PD-L2 based immune signature confers poor prognosis in HNSCC

PD-L2 based immune signature confers poor prognosis in HNSCC

PD-L2 expression is an important predictor of anti-PD-1 therapy efficacy in patients with head and neck squamous cell carcinoma (HNSCC). However, whether the PD-L2-based immune signature can serve as a prognostic biomarker for patients with HNSCC remains unclear. Here, we reported that PD-L2 was pos...

Full description

Bibliographic Details
Main Authors: Yu Qiao, Chao Liu, Xiaoyue Zhang, Qianqian Zhou, Yatian Li, Yini Xu, Zhenyue Gao, Yiqi Xu, Lingping Kong, Aifeng Yang, Mei Mei, Yu Ren, Xudong Wang, Xuan Zhou
Format: Article
Language:English
Published: Taylor & Francis Group 2021-01-01
Series:OncoImmunology
Subjects:
programmed cell death 1 ligand 2
immune signature
head and neck squamous cell carcinoma
interleukin-6
prognosis
Online Access:http://dx.doi.org/10.1080/2162402X.2021.1947569

Similar Items

Similar Items